According to a recent LinkedIn post from Loyal, the company has completed a $100M Series C financing round, bringing total capital raised to more than $250M. The post indicates the round was led by age1 with participation from Baillie Gifford and existing investors, underscoring continued institutional interest in the pet longevity space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that the proceeds are expected to support progression of LOY-002, its lead program for extending lifespan in senior dogs, from late-stage development toward potential market readiness. The post further notes that, if approved, LOY-002 could become the first FDA-approved drug to extend lifespan in any species, which may position Loyal as an early mover at the intersection of veterinary therapeutics and longevity science.
As shared in the post, Loyal links this funding milestone with broader ambitions to develop longevity drugs for dogs, and references commentary from Founder & CEO Celine Halioua in Fast Company on the implications for the business. For investors, the scale and profile of the Series C investors may reduce near-term financing risk while heightening execution risk around regulatory approval timelines and market adoption in a nascent product category.
The post suggests that progressing LOY-002 toward commercialization could, if successful, open a premium-priced segment within the companion animal health market and create optionality for future platforms or adjacent indications. However, revenue realization remains contingent on FDA approval outcomes and the company’s ability to educate veterinarians and pet owners on a novel therapeutic class, factors that will drive the ultimate financial impact of this funding round.